Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

被引：3
|
作者：
Scherpereel, Arnaud
Mazieres, Julien
Greillier, Laurent
Do, Pascal
Bylicki, Olivier
Monnet, Isabelle
Corre, Romain
Audigier-Valette, Clarisse
Locatelli-Sanchez, Myriam
Molinier, Olivier
Thiberville, Luc
Urban, Thierry
Ligeza-Poisson, Catherine
Planchard, David
Amour, Elodie
Morin, Franck
Denis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8507
引用
收藏
页数：6
相关论文
共 34 条
  • [11] Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
    Zalcman, Gerard
    Peters, Solange
    Mansfield, Aaron Scott
    Jahan, Thierry Marie
    Popat, Sanjay
    Scherpereel, Arnaud
    Hu, Wenhua
    Selvaggi, Giovanni
    Baas, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [12] Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
    Zalcman, G.
    Flandin, A-C. Madroszyk
    Molinier, O.
    Dayen, C.
    Egenod, T.
    Debieuvre, D.
    Beaucaire-Danel, S.
    Dixmier, A.
    Pichon, E.
    Girodet, S. Galland
    Giroux-Leprieur, E.
    Cloarec, N.
    Cadranel, J.
    Otto, J.
    Romand, P.
    Langlais, A.
    Morin, F.
    Antoine, M.
    Westeel, V.
    Toffart, A. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S992 - S992
  • [13] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
    Zalcman, G.
    Oulkhouir, Y.
    Cornelissen, R.
    Greillier, L.
    Cid, J. R. Rodriguez
    Mazieres, J.
    Briggs, P.
    Nowak, A. K.
    Tsao, A.
    Fujimoto, N.
    Peters, S.
    Mansfield, A. S.
    Popat, S.
    Nassar, A.
    Bushong, J.
    Hu, N.
    Spires, T.
    Balli, D.
    Eccles, L.
    Baas, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1438 - S1439
  • [14] TWO-YEAR OVERALL SURVIVAL (OS) RATES FROM A RANDOMIZED PHASE 2 TRIAL EVALUATING THE COMBINATION OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) VERSUS IPI IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew H.
    Ott, Patrick A.
    Jiang, Joel
    Horak, Christine
    Wolchok, Jedd D.
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 130 - 131
  • [15] Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
    Zalcman, Gerard
    Mazieres, Julien
    Margery, Jacques
    Greillier, Laurent
    Audigier-Valette, Clarisse
    Moro-Sibilot, Denis
    Molinier, Oliver
    Corre, Romain
    Monnet, Isabelle
    Gounant, Valerie
    Janicot, Henri
    Gervais, Radj
    Locher, Chrystele
    Milleron, Bernard
    Quan Tran
    Lebitasy, Marie Paule
    Morin, Franck
    Creveuil, Christian
    Parienti, Jean-Jacques
    Scherpereel, Arnaud
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [16] Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
    Schadendorf, D.
    Dummer, R.
    Ribas, A.
    Robert, C.
    Sullivan, R. J.
    King, A.
    Polli, A.
    di Pietro, A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S700 - S700
  • [17] Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial
    Fushida, Sachio
    Kinoshita, Jun
    Kaji, Masahide
    Oyama, Katsunobu
    Hirono, Yasuo
    Tsukada, Tomoya
    Fujimura, Takashi
    Ohta, Tetsuo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2353 - 2358
  • [18] Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial
    Zalcman, Gerard
    Madroszyk, Anne
    Dayen, Charles
    Molinier, Olivier
    Egenod, Thomas
    Debieuvre, Didier
    Beaucaire-Danel, Sophie
    Dixmier, Adrien
    Pichon, Eric
    Galland-Girodet, Sigole Ne
    Leprieur, Etienne Giroux
    Cloarec, Nicolas
    Cadranel, Jacques
    Otto, Josiane
    Pote, Nicolas
    Langlais, Alexandra
    Morin, Franck
    Antoine, Martine
    Westeel, Virginie
    Toffart, Anne-Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [19] Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
    Schadendorf, D.
    Hassel, J. C.
    Fluck, M.
    Eigentler, T.
    Loquai, C.
    Berneburg, M.
    Gutzmer, R.
    Meier, F.
    Mohr, P.
    Hauschild, A.
    Becker, J. C.
    Menzer, C.
    Kiecker, F.
    Dippel, E.
    Simon, J-C.
    Conrad, B.
    Garbe, C.
    Koerner, S.
    Livingstone, E.
    Zimmer, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [20] Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Bendell, Johanna C.
    Nemunaitis, John
    Vukelja, Sasha J.
    Hagenstad, Christopher
    Campos, Luis T.
    Hermann, Robert C.
    Sportelli, Peter
    Gardner, Lesa
    Richards, Donald A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4394 - 4400
1234